Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
1.000
-0.040 (-3.85%)
At close: Apr 9, 2026
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
4.45
Revenue / Employee
24.04K
Employees
27
Market Cap
2.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CASI Pharmaceuticals | 26.85M |
| GPL Holdings | 376.54K |
| AXIM Biotechnologies | 92.90K |
| Enzolytics | 46.59K |
| Oncology Pharma | 10.21K |
Vaccinex News
- 11 months ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 1 year ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 1 year ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 1 year ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 1 year ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire